Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction/objectives: The prevalence of heart failure (HF) in the United States is currently at an all-time high and is predicted to rise to 8.5 million by 2030. Development of HF differs between men and women. We examined the risk factors associated with HF in women compared to men.
Methods: A retrospective medical record review of adult men and women with HF. Variables were compared between women and men with Heart failure with Preserved Ejection Fraction (HFpEF) or Heart Failure with Reduced Ejection Fraction (HFrEF).
Results: There were 460 women with HFpEF (WHFpEF) and 258 men with HFpEF (MHFpEF). Higher prevalences were observed in WHFpEF group compared to the MHFpEF group for older age (82.2 ± 9.5 vs 80.6 ± 9.6 years; = .029), asthma (34.3 vs 20.2%; < .001), osteoarthritis (66.5 vs 50.0%; < .001), depression (39.6 vs 23.6%; < .001), hypothyroidism (38.0 vs 17.1%; < .001), and anxiety (43.0 vs 20.9%; < .001). Greater odds of HFpEF in women was observed with increasing age per year (OR = 1.043, 95% CI = 1.027-1.059; < .001), increasing BMI (OR = 1.037, 95% CI = 1.018-1.056; < .001), rheumatological disorder (OR = 1.920, 95% CI = 1.457-2.530; < .001), mental health disorder, such as depression or anxiety (OR = 1.898, 95% CI = 1.459-2.470; < .001), asthma (OR = 1.807, 95% CI = 1.350-2.420; < .001), and hypothyroidism (OR = 1.973, 95% CI = 1.486-2.618; < .001). Among HFrEF patients, 225 patients were in WHFrEF group and 250 patients were in MHFrEF group. Higher prevalences were observed in WHFrEF group compared to the MHFrEF group for asthma (26.7 vs 16.8%; = .009), depression (40.0 vs 22.0%; < .001), hypothyroidism (32.0 vs 20.0%; = .003), and anxiety (32.9 vs 21.6%; = .006). Greater odds of HFrEF in women was noted for Black race (OR = 1.455, 95% CI = 1.018-2.080; = .039).
Conclusion: In women with HF, old age, elevated BMI and osteoarthritis are associated with HFpEF; Black race is associated with HFrEF; while asthma, depression, anxiety, and hypothyroidism are associated with both HFpEF and HFrEF.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12374113 | PMC |
| http://dx.doi.org/10.1177/21501319251367840 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Large-Scale Proteomics-Based Risk Score for the Prediction of Incident Cardio-Kidney-Metabolic Disease Risk.
Circ Genom Precis Med
September 2025
Division of Cardiology, Emory University School of Medicine, Atlanta, GA. (A.K.Y., A.C.R., L.S.S., A.A.Q., Y.V.S.).
Background: Cardio-kidney-metabolic (CKM) disease represents a significant public health challenge. While proteomics-based risk scores (ProtRS) enhance cardiovascular risk prediction, their utility in improving risk prediction for a composite CKM outcome beyond traditional risk factors remains unknown.
Methods: We analyzed 23 815 UK Biobank participants without baseline CKM disease, defined by -Tenth Revision codes as cardiovascular disease (coronary artery disease, heart failure, stroke, peripheral arterial disease, atrial fibrillation/flutter), kidney disease (chronic kidney disease or end-stage renal disease), or metabolic disease (type 2 diabetes or obesity).
Relationships of Circulating Plasma Metabolites With the QT Interval in a Large Population Cohort.
Circ Genom Precis Med
September 2025
Clinical Pharmacology and Precision Medicine, William Harvey Research Institute, London, United Kingdom (W.J.Y., M.M.S., J.R., S.v.D., H.R.W., A.T., P.B.M.).
Background: There is a higher prevalence of heart rate corrected QT (QTc) prolongation in patients with diabetes and metabolic syndrome. QT interval genome-wide association studies have identified candidate genes for cardiac energy metabolism, and experimental studies suggest that polyunsaturated fatty acids have direct effects on ion channel function. Despite this, there has been limited study of metabolite concentration relationships with QT intervals.
View Article and Find Full Text PDF[Biomarkers for an early detection of patients at risk of renal or cardiovascular disease].
Rev Med Liege
September 2025
Service de Chimie clinique, CHU Liège, Belgique.
Chronic kidney disease (CKD), heart failure (HF) and atherosclerotic cardiovascular disease (ASCVD) are pathologies that may remain silent for a long time and thus are largely underdiagnosed in clinical practice. The use of biomarkers may help detect people already suffering from these diseases at an early stage or at increased risk to develop them in a near future. The aim of this article is to discuss the place of the assays of albuminuria, natriuretic peptide (BNP/proBNP) and high-sensitivity troponin as well as lipoprotein(a) to help in the diagnosis and prognosis assessment of individuals at risk of presenting or developing a CKD, HF or ASCVD.
View Article and Find Full Text PDFA Novel Technique to Extract Implanted Leads Using Simple Stylets and Reused Rotational Sheaths in Patients with a Cardiac Implantable Electronic Device.
Turk Kardiyol Dern Ars
September 2025
Division of Arrhythmia and Electrophysiology, Department of Cardiology, University of Health Sciences, Yuksek Ihtisas Cardiovascular Building, Ankara City Hospital, Ankara, Türkiye.
Objective: Transvenous lead extraction (TLE) is used in various clinical scenarios, such as device-related infections. Mechanically powered sheaths are one of the most commonly used tools for TLE procedures. We evaluated the procedural and clinical outcomes of a novel extraction technique for chronically implanted leads in the treatment of device-related infections.
View Article and Find Full Text PDFUse of atrial flow regulator device in children and patients with CHD: a literature review.
Cardiol Young
September 2025
Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
The Occlutech Atrial Flow Regulator is a self-expandable double-disc nitinol device with a central fenestration designed to create a calibrated communication across the interatrial septum. It has been used in adult patients with heart failure and pulmonary hypertension. Its use in the paediatric population or adults with CHD has been published in several case reports and case series.
View Article and Find Full Text PDF